Black Diamond Therapeutics, Inc. - Common Stock (BDTX)
1.3700
-0.1400 (-9.27%)
NASDAQ · Last Trade: Apr 5th, 4:41 PM EDT
Detailed Quote
Previous Close
1.510
Open
1.460
Bid
1.390
Ask
1.450
Day's Range
1.360 - 1.510
52 Week Range
1.360 - 7.660
Volume
1,932,389
Market Cap
49.61M
PE Ratio (TTM)
-1.079
EPS (TTM)
-1.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
7,443,946
Chart
About Black Diamond Therapeutics, Inc. - Common Stock (BDTX)
Black Diamond Therapeutics is a biotechnology company focused on developing innovative medicines for people with serious neurological and neurodegenerative diseases. The company leverages its proprietary technology platform to create targeted therapies that specifically address the underlying causes of these conditions, striving to improve patient outcomes and quality of life. With a commitment to scientific advancement, Black Diamond Therapeutics aims to translate its discoveries into effective treatments through a rigorous research and development process. Read More
CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone payments.
SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors. Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.
CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update.
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows potential to address osimertinib resistance.
Pre-market trading is heating up as Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) surges on positive Phase 2 data for its cancer treatment BDTX-1535. Peraso Inc. (NASDAQ: PRSO) continues its expansion into the Asian markets and a major military contract. Kaival Brands (NASDAQ: KAVL) saw its stock surge in early trading today on merger announcement. Other stocks to watch include Banzai International Inc. (NASDAQ: BNZI), which saw a 97.51% rally after announcing a favorable share structure, Battalion Oil Corp (NASDAQ: BATL) on merger news, and Treasure Global Inc. (NASDAQ: TGL) , experiencing unusual high volume on its innovative ZCITY Super App. Keep these stocks on your radar for potential moves. See more in-depth information below.
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre’s Board of Directors (the “Board”), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board.
